Lilly and Biogen: “A Fertile Period” In Alzheimer’s Research

Eli Lilly & Co. ( LLY ) and Biogen ( BIIB ) are far from the only two drug makers racing to deliver a new treatment for Alzheimer’s disease. But they are pretty much leading the pack. The market for an effective therapy that actually slows the progression of the disease would likely generate billions of dollars in annual sales. It is quite literally the drug industry’s version of the “holy grail.” And according to Barclays analysts Geoff Meacham and Paul Choi , “the next few weeks could prove to be one of the most fertile periods in Alzheimer’s disease research” since 2008.